HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warnings: Mariposa Done With OTCs, Thibiant's Long Correction List

Executive Summary

GMP violations FDA inspectors found at Mariposa Labs' plant were repeats of a previous inspection. Thibiant International's problems included was "knowing the formulation was flawed" but making "a second batch using the same formulation."

You may also be interested in...

Scientific Solutions Global's Formulations Miss OTC Monographs Mark – FDA

Firms' BioTemper, bare and Urea brand products, as formulated and labeled, are unapproved drugs that need approval through NDAs before being sold in US, FDA says in warning. Separate websites firm operates for each brand continues offering sales.

CBD Oral Sprays For Pain, Sleep, Weight Recalled On Microbial Contamination

First report of salmonella contamination for a kratom supplement in nearly nine months prompts Sunstone Organics to recall one lot each of its white vein and maeng da types of the herb. FDA's latest recall database update includes Nutrafuels' recall of more than 1,500 of its CTFO Oral Spray with pure CBD hemp oil isolate dietary supplements for sleep support, weight loss and pain relief after third-party testing showed microbial contamination.

Warnings Up As FDA Trims Its List Of Uninspected OTC Drug Manufacturers

Hundreds of foreign OTC drug firms marketing products in US had not been inspected for GMP compliance before FDA Safety and Innovation Act of 2012 pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and January 2018, 25% received "official action indicated" inspection results, prompting warning letters and import alerts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts